April 2025 — Responding to the rising demand for innovative nano-enabled therapeutics, Litchlab today announced the official launch of its Gold Nanoparticle (GNP) Drug Delivery CDMO Platform, offering a comprehensive suite of services from early-stage formulation to GMP production and regulatory support. This new platform positions Litchlab as a strategic partner for biopharmaceutical companies exploring precision therapies in oncology, immunotherapy, infectious diseases, and diagnostics.
As the global CDMO market shifts towards high-value, technology-driven offerings, gold nanoparticles are emerging as a transformative tool. Their unique physicochemical properties — including excellent biocompatibility, facile surface modification, photothermal effects, and tunable size — make them ideal carriers for targeted drug delivery, gene therapy, and theranostics.
✅ Custom GNP Synthesis and Functionalization
Size tuning from 5 nm to 100 nm
Surface engineering with PEGylation, targeting ligands (antibodies, peptides), or nucleic acid conjugation
Multimodal loading: chemotherapeutics, siRNA/mRNA, proteins
✅ Versatile Delivery Applications
Tumor-targeted drug delivery (passive and active targeting)
Gene editing (CRISPR/Cas9 delivery systems)
Vaccine adjuvant development (e.g., mRNA, DNA vaccines)
Diagnostic imaging agents (photothermal, photoacoustic, fluorescence)
✅ Advanced Process Development and GMP Manufacturing
Scale-up from milligram to multi-gram GMP batches
Sterile production technologies
Stability optimization under physiological conditions
Customized surface charge, hydrophilicity, and pharmacokinetics control
✅ Comprehensive Analytical and Regulatory Support
Particle size, zeta potential, drug loading efficiency, and release kinetics analysis
In vitro cytotoxicity and hemocompatibility testing
Compliance with FDA, EMA, NMPA guidelines for IND/IMPD submissions
Recent reports show that the global nanomedicine market is expected to reach USD 400 billion by 2032, with gold nanoparticles playing a critical role in targeted oncology, vaccine delivery, and minimally invasive diagnostics.
Major pharmaceutical companies and biotech startups alike are investing heavily in GNP platforms to differentiate their pipelines with precision delivery capabilities.
With its forward-looking GNP platform, Litchlab is strategically aligned with this trend, providing a flexible, scalable, and fully regulatory-compliant service to accelerate the clinical translation of next-generation therapeutics.
✔️ Full-suite CDMO services tailored for GNP-based drug delivery
✔️ Expertise in nanomaterial synthesis, functionalization, and conjugation
✔️ Seamless integration with other delivery systems (liposomes, micelles, hydrogels)
✔️ Complete GMP production and global regulatory filing support
✔️ Agile and collaborative project management for accelerated timelines
"Gold nanoparticles are unlocking new frontiers in personalized medicine and smart therapeutics." said Dr. Liu Tao, COO of Litchlab.
"We are committed to providing our global partners with cutting-edge, customizable nanoplatform solutions to bring more effective treatments to patients worldwide."
📞 Ready to transform your drug delivery strategy with gold nanoparticles?
Connect with Litchlab and start your journey toward next-generation nanomedicine today.
🔗 Learn more: www.litchlab.com
📧 Contact us: Sales@litchlab.com
